Serum immunoglobulin G is a marker for the risk of opportunistic infection in steroid-dependent severe asthmatic patients

Internal Medicine

Volumn 51, Issue 19, 2012, Pages 2715-2719

  Yomota, Makiko ^a   Amano, Izuki ^a   Horita, Nobuyuki ^a   Takezawa, Tomoko ^a   Arai, Takahiko ^a   To, Masako ^a,b   To, Yasuo ^a  

^a Fraternity Memorial Hospital   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Corticosteroid; Opportunistic infection; Serum immunoglobulin G; Severe asthma

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN G; MUSCARINIC RECEPTOR BLOCKING AGENT; SERUM ALBUMIN; TEICOPLANIN; THEOPHYLLINE; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASTHMA; CANDIDIASIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; HERPES ZOSTER; HUMAN; MALE; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMONIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RISK FACTORS; ROC CURVE;

EID: 84867770892     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7775     Document Type: Article

References (16)

1. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157 (3 Pt 2): S1-S53, 1998.
2. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticoster-oids and the long term prevention of hospitalisation for asthma. Thorax 57: 880-884, 2002.
3. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose in-haled corticosteroids and the prevention of death from asthma. N Engl J Med 343: 332-336, 2000.
4. Wenzel SE, Busse WW. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 119: 14-21, 2007.
5. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 82: 704-708, 1998.
6. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 15: 423-432, viii, 2001.
7. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11: 954-963, 1989.
8. Gloval Initiative for asthma Global Strategy for Asthma Manage-ment and Prevention. 2006.
9. Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician 58: 443-450, 1998.
10. Bland JM, Altman DG. Statistical methods for assessing agree-ment between two methods of clinical measurement. Lancet 1: 307-310, 1986.
11. Barnes PJ. Immunology of asthma and chronic obstructive pulmo-nary disease. Nat Rev Immunol 8: 183-192, 2008.
12. Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest 75: 754-761, 1985.
13. Curtis JL. Cell-mediated adaptive immune defense of the lungs. Proc Am Thorac Soc 2: 412-416, 2005.
14. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 129: 569-582, 2005.
15. Romani L. Immunity to fungal infections. Nat Rev Immunol 11: 275-288, 2011.
16. Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 4: 288-293, 2011.